替加环素治疗碳青霉烯类耐药革兰阴性菌医院获得性肺炎的临床研究

发布时间：2017-12-28 14:05

本文关键词：替加环素治疗碳青霉烯类耐药革兰阴性菌医院获得性肺炎的临床研究　出处：《中华医院感染学杂志》2016年23期 　论文类型：期刊论文

【摘要】：目的研究替加环素(TGC)对碳青霉烯类耐药革兰阴性菌(CRGNB)所致重症医院获得性肺炎(HAP)、呼吸机相关性肺炎(VAP)的临床疗效,为临床治疗提供参考依据。方法回顾分析2013年1月-2015年12月医院呼吸HAP/VAP患者,其中TGC治疗33例为治疗组,18例为对照组;分析其临床及微生物学资料、治疗情况等。结果治疗组有效率、清除率、ICU病死率与对照组比较,差异有统计学意义(P0.05);抗菌药物使用时间、机械通气时间、ICU住院时间、及治疗后30d全因病死率两组比较差异无统计学意义。结论对于入住ICU的CRGNB所致HAP/VAP患者,TGC联合抗感染治疗是为数不多的可供选择的有效治疗方法之一。
[Abstract]:Objective to study the clinical efficacy of tegafycline (TGC) on carbapenem resistant gram-negative bacteria (CRGNB) caused by severe hospital acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), so as to provide reference for clinical treatment. Methods a retrospective analysis of respiratory HAP/VAP patients in hospital from January 2013 to December -2015, including 33 cases of TGC treatment, 18 cases of control group, and analysis of clinical and microbiological data, treatment and so on. Results the effective rate, clearance rate and ICU mortality rate in the treatment group were significantly different from those in the control group (P0.05). There was no significant difference in the time of antibiotic use, mechanical ventilation time, ICU hospitalization time and 30d all-cause mortality between the two groups. Conclusion TGC combined with anti infection treatment is one of the few effective treatments for HAP/VAP patients in HAP/VAP induced by ICU.
【作者单位】：浙江省台州医院呼吸内科;
【基金】：恩泽医疗中心(集团)科学研究基金(14EZD12)
【分类号】：R563.1
【正文快照】： 碳青霉烯类耐药革兰阴性菌(CRGNB)医院感染逐年增加,尤其医院获得性肺炎(HAP)和呼吸机相关性肺炎(VAP)。因其广泛的耐药性,CRGNB导致的HAP和VAP治疗难度大、病死率高,已成为临床工作中的巨大挑战[1]。替加环素(TGC)是具有广谱抗菌活性的甘氨酰环素类抗菌药物。体外研究显示TGC

【相似文献】